FDA
-
-
-
-
-
-
-
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
-
-
-
-
-
-
-
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
-
-
-
-
-
-
-
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
-
-
-
-
-
-
-
Gain Therapeutics (GANX) Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287
-
-
-
-
-
-
-
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
-
-
-
-
-
-
-
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

